About Myoblast determination protein 1
Myoblast determination protein 1 (MYOD1) is a protein
from Homo sapiens identified by UniProt accession
P15172, 320 residues long.
MolForge cross-references it against 0 known binders and
305 disease associations.
Target properties
| Protein name | Myoblast determination protein 1 |
| UniProt accession | P15172 |
| Gene | MYOD1 |
| Organism | Homo sapiens |
| Length | 320 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (305)
Diseases linked to this target (Open Targets).
- myopathy, congenital, with diaphragmatic defects, respiratory insufficiency, and dysmorphic facies · score 0.61
- neurodegenerative disease · score 0.46
- rhabdomyosarcoma · score 0.44
- embryonal rhabdomyosarcoma · score 0.37
- gastric carcinoma · score 0.37
- cecum adenocarcinoma · score 0.37
- colorectal adenocarcinoma · score 0.37
- fetal akinesia deformation sequence · score 0.37
- gastric adenocarcinoma · score 0.37
- autosomal dominant centronuclear myopathy · score 0.34
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P15172-F1 | alphafold | PREDICTED | 61.17 | — |
Amino-acid sequence (320 residues)
MELLSPPLRD VDLTAPDGSL CSFATTDDFY DDPCFDSPDL RFFEDLDPRL MHVGALLKPE EHSHFPAAVH PAPGAREDEH VRAPSGHHQA GRCLLWACKA CKRKTTNADR RKAATMRERR RLSKVNEAFE TLKRCTSSNP NQRLPKVEIL RNAIRYIEGL QALLRDQDAA PPGAAAAFYA PGPLPPGRGG EHYSGDSDAS SPRSNCSDGM MDYSGPPSGA RRRNCYEGAY YNEAPSEPRP GKSAAVSSLD CLSSIVERIS TESPAAPALL LADVPSESPP RRQEAAAPSE GESSGDPTQS PDAAPQCPAG ANPNPIYQVL
Explore Myoblast determination protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets